Research programme: vitiligo therapy - SWITCH Biotech

Drug Profile

Research programme: vitiligo therapy - SWITCH Biotech

Alternative Names: SWT 05.100; SWT 05.102; SWT 05.103; SWT 05100; SWT 05102; SWT 05103; Vitiligo therapies research programme - SWITCH Biotech

Latest Information Update: 02 Jun 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SWITCH Biotech (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Vitiligo

Most Recent Events

  • 01 Mar 2005 Discontinued - Preclinical for Vitiligo in Germany (unspecified route)
  • 01 Mar 2005 SWITCH Biotech has closed down
  • 30 Mar 2004 SWITCH Biotech AG and Spirig Pharma AG have entered into an agreement to co-develop SWT 05.100 for vitiligo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top